Item 7.01 Regulation FD Disclosure.
On
The investor presentation is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K, and a replay of the webcast will be available on the "Investors" section of the Company's website at ir.soligenix.com.
Forward-looking Statements
The investor presentation and webcast contain forward-looking statements as
defined in the Private Securities Litigation Reform Act of 1995. The words
"anticipate," "appears," "believe," "estimate," "expects," "plan," "intend,"
"will," "aim," "should," "could," "is on track," "may," "continue to," "if,"
"growing," "projected," "potential," "likely," and similar expressions, as they
relate to us, are intended to identify forward-looking statements, but the
absence of these words does not mean that a statement is not forward-looking.
All statements other than statements of historical facts contained therein,
including statements regarding the Company's future results of operations and
financial position, business strategy, prospective products and product
candidates and their development, regulatory approvals, ability to commercialize
products and product candidates and attract collaborators, reimbursement for the
Company's product candidates, research and development costs, timing and
likelihood of success, plans and objectives of management for future operations,
the Company's ability to obtain and maintain intellectual property protection
for its product candidates and their development, competing therapies, and
future results of current and anticipated products and product candidates, are
forward-looking statements. These statements involve known and unknown risks,
uncertainties, and other important factors that may cause the Company's actual
results, performance or achievements to be materially different from any future
results, performance or achievements expressed or implied by the forward-looking
statements, many of which are disclosed in detail in the Company's reports and
other documents filed with the
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits. Exhibit No. Description 99.1 Investor Presentation - "U.S. Commercialization of SGX301 in the Treatment of Cutaneous T-Cell Lymphoma." 1
© Edgar Online, source